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Dysregulation of Human Phase I Enzymes in 
AP AP Overdose Subjects with Low AL T Levels 
Aaron Woodall 
Background: Acetaminophen (APAP) is a common analgesic that can cause liver injury and death 
in high doses. Changes in gene expression following AP AP overdose may be more sensitive 
indicators of liver injtrry than the current clinical indicator, alanine aminotransferase (AL T). The aim 
of this study was to examine gene expression of Phase I enzymes in pediatric AP AP overdose 
patients with low ALT levels (<75 lUlL), in order to understand the mechanism of APAP toxicity. 
Methods: Blood samples were collected from control patients (no AP AP exposure; N=5) and APAP 
overdose patients {N=S). Using the P AXgene system, RNA was extracted from the blood samples 
and eDNA was synthesized. Quantitative polymerase chain reaction (qPCR) was performed and 
samples were profiled with an array containing 84 Phase I Enzyme drug metabolism genes. 
Results: The low ALT pediatric APAP overdose patients had higher (median [range]) ALT levels 
(35 [25,48] lUlL) compared to controls (16 [7, 20] IUIL). Three genes had significant 
downregulation that was later confirmed: GZMB (-2.86 fold, p<O.O I), ALDH6A 1 (-2.13 fold, 
p<O.Ol), and CYP4F12 (-4.04 fold, p<O.OS). Pathway analysis for the three genes pointed to 
signaling pathways connected to apoptosis, metabolism of valine and leucine (involved in the 
immune response), and hydroxylation of leukotriene B4 (involved in inflammation). 
Conclusion: Dysregulation of Phase I Enzyme drug metabolism pathways has relevance for 
understanding mechanisms of cell injury in AP AP toxicity. Pathway analysis points to the potential 
for a weakened immune response associated with AP AP overdose. 
INTRODUCTION 
Acetaminophen (APAP) is a mild analgesic 
found in many over-the-counter drugs. Taken in 
normal doses, it is generally regarded as safe 
and non-toxic, though liver injwy is common. 
AP AP overdose is the leading cause of acute 
liver failure in the United States [6]. 
Acetaminophen overdose is a common 
problem in the United States. A 2015 study 
(conducted from 2006-20 I 0) showed that in the 
United States alone, 82,362 people visited the 
emergency room every year for APAP 
overdose. Every year, there were roughly 494 
deaths caused by acetaminophen toxicity [1]. 
APAP toxicity does not have a clearly 
defined limit. Tylenol, the largest and most 
well-known distributer of APAP, recommends a 
maximum daily dosage of 3,000 mg for adults. 
For children, this amount greatly varies by 
weigh l and age [ I 0]. Nonetheless, the 
acetaminophen toxicity limit varies from person 
to person. 
The clinical biomarker for APAP overdose is 
alanine aminotransferase (ALT). Raised AL T 
levels indicate liver injwy, but this is not 
specific to acetaminophen (6]. APAP adducts 
arc fonncd in the metabolism of acetaminophen. 
AP AP is metabolized by Phase I enzymes in the 
cytochrome P450 family (namely CYP2El) into 
N-acetyl-p-benzoquinone imine (NAPQI), a 
toxic reactive intermediate metabolite. When 
NAPQI binds to the cysteine group on a protein, 
APAP adducts are formed [7]. In a therapeutic 
dose of AP AP, this material is detoxified by 
glutathione and is excreted. Thus, these adducts 
are only present in patients who have exceeded 
the normal dosage of APAP and present liver 
il\iury [6, 7]. 
The lab previously studied APAP overdose 
in patients with severe liver injury, defined as 
having ALT levels >75 TU/L. The five high 
ALT blood samples were run in qPCR against 
five control samples, and three genes were 
identified as being dowmegulated (using a 2-
fold and p<0.05 cut-oft): ALDHlAl, 
CYP27Al, and GZMB. The downregulation of 
all three genes was confirmed by individual 
analysis. 
This study functioned as a follow-up to the 
high AL T experiment and a conclusion to the 
lab's PA.Xgene APAP overdose project. In this 
study, we investigated gene dysregulation of 
APAP overdose patients who exhibited mild 
liver injury, or low AL T levels, to better 




The study focused on pediatric AP AP 
overdose patients with low AL T levels from 
Arkansas Children's Hospital. Patients who 
were in the hospital due to AP AP overdose and 
presented a mild liver injury, defined as ALT 
levels <75 IU/L, were identified and selected for 
the study. Blood samples were collected by 
nurses who were aware of the study and 
delivered to the lab for research. ALT levels and 
AP AP adduct levels were measured for each 
sample. Blood samples were stored in PAXgene 
Blood RNA tubes (PreAnalytiX, GmbH, 
Switzerland). This study included five AP AP 
overdose samples (low ALT levels) and five 
control samples (randomly identified and 
2 
selected with no AP AP influence in the last two 
weeks). 
RNA Isolation and eDNA Synthesis 
The PA.Xgcnc Blood miRNA system was 
used for the purification of total RNA from 
peripheral blood collected in P A.Xgene Blood 
RNA Tubes. PAXgene-extracted RNA was 
quantified using spectrophotometer 
(NanoDrop™ 1000, Thenno Fisher Scientific, 
Wilmington, DE). eDNA synthesis was 
performed using the RT2 First Strand kit 
(Qiagen). 
Phase I PCR Array 
For target gene expression analysis, Phase I 
Enzymes RP Profiler™ PCR Array (PAHS~ 
068Z), which contains 84 genes involved in 
Phase I drug metabolism, were used with the 
SYBR®Green system (Qiagen). The ABI 
QuantStudio 6 Flex Real Time PCR cycler 
(Applied Biosystems) was used to perfonn 
quantitative real-time PCR (qPCR). All 
experiments were performed in DNase/RNase 
free conditions and n01malized to GAPDH. The 
analysis was performed by Threshold Cycle 
Method and the fold change obtained by the 
delta CT method. Qiagen's qPCR analysis tool, 
available on 
http://pcrdataanalysis.sabiosciences.com/pcr/arr 
ayanalysis.php, was used for analysis. The 
Volcano plot considered genes that had 2:2 fold 
change and a p-value <0.05 in the t-test. 
eDNA Expression Analysis 
Quantitative real time PCR (qPCR) was 
performed for all samples in triplicate on 
QuantStudioTM 6 Flex Real-Time PCR System 
(TbermoFisher Scientific, Carlsbad, CA). qRT-
PCR quantification of eDNA expression was 
performed using assays and accompanying 
reagents from Qiagen eDNA analyses were 
performed using Primer Assays for aldehyde 
dehydrogenase 6 family, member Al 
(ALDH6A l; PPH16308B), Cytochrome P450 
family 4, subfamily F, polypeptide 12 
(CYP4Fl2, PPH01237F), Granzyme B (GZMB; 
PPH02594A), and Beta Actin ( ACTB; 
PPH00073G). For each primer assay, negative 
controls were run with water and eDNA 
samples. For no template controls (NTC) a 
master mix with no eDNA was used. Data 
normalization was performed with ACTB. 
Relative quantitation was calculated using the 
delta CT method. Pathway analysis was 
performed for each of the identified genes using 
The Human Gene Database available at 
http://www.genecards.org/. 
RESULTS 
The ALT levels and AP AP adduct levels in 
the AP A overdose low AL T group were 
significantly higher than those in the control 














The qpCR array, analyzed with the Qiagen 
web portal qPCR analysis tool, identified three 
genes as dysregulated, defined as having a fold 
change =:::2 and a p-value <0.05. They were 
identified on a volcano plot that plots -log( fold 
change) against -log(p-value) for each of the 84 
genes profiled in the qPCR array (Figure 
2).ALDH6Al , GZMB, and CYP4F 12 were all 
identified as downrcgulated in the low AL T 
AP AP overdose samples. The individual qPCR 
validation assays confirmed the downrcgulation 
of all three genes (Figure 3). 
GeneCards' reported pathway analysis shows 
that ALDH6Al is involved in metabolic 
pathways in the degradation of valine, leucine, 
and isoleucine [2]~ GZMB is involved in the 
Granzyme-B pathway of the immune response, 
specifically in apoptosis [ 4]; and CYP4Fl2 














Figure 1: Sample data for control and AP AP overdose (low ALT) groups. The test group had higher 
ALT levels (p=0.0017) and significantly higher APAP adduct levels (p=0.0030). 
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Figure 2: Volcano plot that identifies dysregulated genes. Plots -log( fold change) against -log(p-
value). Three genes were identified as downregulated: GZ:MB, ALDH6Al, and CYP4Fl2. 
Initial Initial Validation 
Gene Fold p-value Fold 
Change Change 
ALDH6Al -2.1281 0.00588 -1.5945 
GZMB -2.8555 0.00201 -1.3148 
CYP4Fl2 -4.0393 0.01208 -6.6555 
Figure 3: Fold change values for dysregulated genes. Initial fold change values and p-values 
identified with volcano plot from initial qPCR array. Validation fold change values identified using 
delta CT method from individual validation qPCR assays. 
DISCUSSION 
Based on this study, ALDH6Al, GZMB, and 
CYP4F12 are all downregulated in pediatric 
needed to confitm these results, as the sample 
size was limited to the patients available in the 
hospital. 
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AP AP overdose patients with mild liver injury 
from Arkansas Children's Hospital. Further 
research that expands the P AXgcne database is 
The most interesting results come from the 
pathway analysis of the three genes, and the 
related damage that APAP overdose may cause. 
ALDH6A 1 is involved in the metabolism of 
three branched chain amino acids (BCAAs) [2]. 
Valine, leucine, and isoleucine are the three 
essential BCAAs that facilitate glucose uptake 
in the liver and aid in protein synthesis. 
Research suggests that impairing the 
degradation of BCAAs leads to their buildup 
and can produce toxic materials. BCAAs are 
also essential for the growth of lymphocytes and 
cytotoxic T cell activity, meaning that they play 
an important role in the immune response [9). 
With the downregulation of an enzyme that 
metabolizes these amino acids, their activity and 
role in the immune response would potentially 
be weakened. Further research to find a link 
between AP AP overdose and the 
downregulation of ALDH6Al is needed, but 
this study may suggest a pathway of liver injury 
through BCAAs, as well as a weaker immune 
response as a result. 
GZMB is involved in the immune response 
[ 4]. It is released by natural killer ceUs and 
cytotoxic T cells to induce target cell apoptosis. 
GZMB also plays a role in chronic 
inflammation and wound healing [ 5]. A 
downregulation of this gene may cause a 
weakened immune response. GZMB was also 
found to be downregulated in a previous study, 
mentioned above, of this lab with AP AP 
overdose patients who presented severe liver 
injury (ALT levels >75 lUlL). A comprehensive 
study will be published in the near future. 
Further research that focuses specifically on the 
role of GZMB in AP AP metabolism is needed 
to confirm these results and establish a 
connection between the gene dysregulation and 
potential cell injuries. 
CYP4F12 is involved in the hydroxylation of 
leukotriene B4 (LTB4) [3]. LTB4 is an epoxide 
that is an inflammatory mediator [8]. 
Inflammation is also an important part of the 
immune response. This suggests that the 
downregulation ofCYP4F12 may affect the 
effectiveness of inflammation and the overall 
immune response. Further research into 
differences of inflammatory responses in 
pediatric AP AP overdose patients would be 
interesting. 
5 
The downregulated genes point to a potential 
weakening of the immune response related to 
APAP overdose, especially in the liver. To 
confitm these suspicions, further research would 
need to be done to confirm the initial 
downregulation of the Phase I enzymes. 
Extensive experimentation would need to be 
conducted with APAP overdose patients that 
tested their immune response. Though not 
conclusive, this study points to a potential for 
cell injury associated with APAP overdose 
outside of the known liver damage. It also gives 
insight into potential biomarkers through the 
affected enzymes. 
ARKANSAS CHILDREN'S RESEARCH 
INSTITUTE 
My summer interning at Arkansas Children's 
Research Institute was an educational and 
highly beneficial experience. Working in Dr. 
Laura James' lab under Dr. Prit Gill, I learned 
valuable laboratory skills and improved upon 
my professional communication. As part of the 
Summer Science Program, I was also able to 
hear from and shadow medical professionals in 
various departments of the hospital. These 
experiences expanded my knowledge and 
helped to prepare me to enter a physician 
assistant program in the coming year, and to one 
day be a health care provider myself. 
While working in the laboratory, I learned 
new lab techniques, including plating samples in 
preparation for qPCR, operating the PCR cycler, 
and data analysis. In addition to my project, I 
had the opportunity to assist in other projects 
that the lab was working on. For a related study, 
researching the effects of acetaminophen 
exposure on mouse Leydig cells, I learned how 
to perform cell culture. This involved splitting 
the cells, preparing acetaminophen doses, 
treating the cells with the drug, and extracting 
RNA to perform qPCR similar to that done with 
the PAXgene blood samples. 
Working closely with Dr. Gill improved my 
professional communication skills. I learned 
how to contribute to meetings by staying up-to-
date on reading articles and learning more about 
the subject, which was all relatively new to me. 
I also spent a lot of my time on my own, so I 
learned to work independently in a lab setting, 
another new experience for me. My internship 
allowed me to network and to develop a 
professional relationship with my mentors that 
will greatly benefit me in the future. 
Aside from researching, the Arkansas 
Children's Research Institute Summer Science 
Program provided twenty-two other students 
and me with opportunities to meet medical 
professionals. Most of us were in college with 
aspirations to attend a medical graduate program 
and practice in the health profession. We 
enjoyed a lecture series twice a week during the 
eight-week program where we heard from 
different professionals, including a 
neonatologist, a geneticist, a pediatric 
psychologist, an emergency medicine physician, 
a neurosurgeon, and others from diverse 
backgrounds and areas. This introduced me to 
areas of medicine that I knew close to nothing 
about, and helped me continue to decide what 
area of medicine I wanted to enter. 
Along with the lectures, the shadowing 
opportunities were immensely beneficial and 
essential to the overall experience. One of the 
most interesting experiences I had was 
shadowing a medical ethicist during his 
pediatric intensive care unit rounds. We 
discussed ethical questions that arose during 
hospital care, and how he worked with the 
physicians to ensure that patients were cared for 
with regard to the best medical practices as well 
as the patient's wishes. It opened my eyes to 
ethical dilemmas I had never considered. I also 
had the chance to shadow in the general 
pediatric surgery unit and the emergency 
department. Both of these were areas I had 
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never experienced from the side of the provider. 
I became very interested in both of these high-
stakes fields and excited at the possibility of one 
day working in one of them. 
However, the most important shadowing 
experience I had was with the physician 
assistant team in cardiovascular surgery. 
Shadowing with the physician assistants 
confirmed my desire to apply for physician 
assistant school and enter the field. I had the 
opportunity to sit in a pre-operation consultation 
day, two different open-heart surgeries, and 
post-operation intensive care rounds. The 
physician assistants worked with their patients 
throughout their entire treatment and I had the 
chance to see all of the aspects. This experience 
inspired me and helped me be accepted into the 
physician assistant program. 
Overall, my summer internship at Arkansas 
Children's Research Institute was highly 
beneficial. I would strongly suggest that those 
who wish to enter to medical field apply for 
similar programs or experiences, as they 
expanded my knowledge and gave me 
invaluable opportunities. Because ofthe 
opportunity to independently research and my 
time spent shadowing and networking with 
medical professionals, I feel better prepared to 
enter into a career in the health care field. 
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